These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9846027)

  • 1. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study.
    Watanabe S; Pereira J; Hanson J; Bruera E
    J Pain Symptom Manage; 1998 Nov; 16(5):323-6. PubMed ID: 9846027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management.
    Paix A; Coleman A; Lees J; Grigson J; Brooksbank M; Thorne D; Ashby M
    Pain; 1995 Nov; 63(2):263-269. PubMed ID: 8628593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
    Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
    Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
    Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
    J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal opioids for cancer pain.
    Skaer TL
    Health Qual Life Outcomes; 2006 Mar; 4():24. PubMed ID: 16573839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
    Yamazaki M; Aoki T; Tachibana M; Akashi T
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):217-21. PubMed ID: 16484859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
    Jackson LD; Wortzman R; Chua D; Selby D
    J Oncol Pharm Pract; 2021 Jan; 27(1):238-243. PubMed ID: 32501183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
    Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
    Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
    Santiago-Palma J; Khojainova N; Kornick C; Fischberg DJ; Primavera LH; Payne R; Manfredi P
    Cancer; 2001 Oct; 92(7):1919-25. PubMed ID: 11745266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous fentanyl infusion: use in severe cancer pain.
    Lenz KL; Dunlap DS
    Ann Pharmacother; 1998 Mar; 32(3):316-9. PubMed ID: 9533063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transdermal route as an alternative to oral administration of opioids in cancer pain].
    Burza M; Ginobbi P; Fusco G; Laurenzi L; Tirelli W; Arcuri E
    Clin Ter; 1998; 149(4):277-80. PubMed ID: 9866889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cancer-related pain with transdermal fentanyl.
    Leelanuntakit S
    J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
    Sittl R; Nuijten M; Poulsen Nautrup B
    Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of fentanyl patch in home palliative care].
    Yoshizawa A; Gyouda Y; Ishiguro T; Yoshizawa T; Yoshida S
    Gan To Kagaku Ryoho; 2003 Dec; 30(1 Suppl):129-31. PubMed ID: 15311783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan].
    Hashizume T; Tomiyasu S; Yomiya K; Yoshimoto T; Harada A; Matoba M;
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):897-902. PubMed ID: 17570968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
    Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
    J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
    Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
    Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
    Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
    Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.